Brief: Argent Biopharma Signs NLC Licence To Expand Antiviral Portfolio
29/09/2026 02:35
BRIEF-Argent Biopharma Signs NLC Licence To Expand Antiviral Portfolio Sept 29 (Reuters) - Argent BioPharma Ltd RGT.AX:
ARGENT SIGNS NLC LICENCE TO EXPAND ANTIVIRAL PORTFOLIO
SIGNS EXCLUSIVE ROYALTY-BEARING LICENCE WITH NLC FOR ANTIVIRAL PRODUCTS
LICENCE TERRITORY IS WORLDWIDE EXCLUDING CHINA; TOLLOHEALTH RIGHTS IN U.S. PRESERVED
NLC ENTITLED TO $100,000 AT $2.5 MILLION NET SALES AND $125,000 AT $5 MILLION NET SALES
Further company coverage: RGT.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Executes Global Licence For Non-Core Cannabis Genetics
Brief: Argent Biopharma Files Provisional US Patent On Immune Modulation And Longevity
Australia's Argent BioPharma rises to over 1-month high on new licence agreement
Brief: Argent Biopharma Signs NLC Licence To Expand Antiviral Portfolio
Brief: Argent Biopharma Says FDA-CVM Established Inad File For Cannepil Veterinary Program